244 related articles for article (PubMed ID: 16224236)
1. Update on angiogenesis inhibitors.
Zakarija A; Soff G
Curr Opin Oncol; 2005 Nov; 17(6):578-83. PubMed ID: 16224236
[TBL] [Abstract][Full Text] [Related]
2. Role of anti-angiogenesis agents in treating NSCLC: focus on bevacizumab and VEGFR tyrosine kinase inhibitors.
Cabebe E; Wakelee H
Curr Treat Options Oncol; 2007 Feb; 8(1):15-27. PubMed ID: 17634832
[TBL] [Abstract][Full Text] [Related]
3. Targeted therapy in advanced non-small-cell lung cancer.
Gettinger S
Semin Respir Crit Care Med; 2008 Jun; 29(3):291-301. PubMed ID: 18506667
[TBL] [Abstract][Full Text] [Related]
4. Drug insight: VEGF as a therapeutic target for breast cancer.
Schneider BP; Sledge GW
Nat Clin Pract Oncol; 2007 Mar; 4(3):181-9. PubMed ID: 17327858
[TBL] [Abstract][Full Text] [Related]
5. Targeting angiogenesis in esophagogastric adenocarcinoma.
Okines AF; Reynolds AR; Cunningham D
Oncologist; 2011; 16(6):844-58. PubMed ID: 21632459
[TBL] [Abstract][Full Text] [Related]
6. Anti-angiogenic therapies for metastatic colorectal cancer.
Wagner AD; Arnold D; Grothey AA; Haerting J; Unverzagt S
Cochrane Database Syst Rev; 2009 Jul; (3):CD005392. PubMed ID: 19588372
[TBL] [Abstract][Full Text] [Related]
7. Emerging data with antiangiogenic therapies in early and advanced non-small-cell lung cancer.
Horn L; Sandler AB
Clin Lung Cancer; 2009 Mar; 10 Suppl 1(Suppl 1):S7-16. PubMed ID: 19362948
[TBL] [Abstract][Full Text] [Related]
8. In pursuit of new anti-angiogenic therapies for cancer treatment.
Cai J; Han S; Qing R; Liao D; Law B; Boulton ME
Front Biosci (Landmark Ed); 2011 Jan; 16(3):803-14. PubMed ID: 21196204
[TBL] [Abstract][Full Text] [Related]
9. VEGF inhibition and metastasis: possible implications for antiangiogenic therapy.
English BC; Price DK; Figg WD
Cancer Biol Ther; 2009 Jul; 8(13):1214-25. PubMed ID: 19483467
[No Abstract] [Full Text] [Related]
10. [Oral drugs inhibiting the VEGF pathway].
Ropert S; Mir O; Armand JP
Bull Cancer; 2007 Jul; 94 Spec No():S180-90. PubMed ID: 17846003
[TBL] [Abstract][Full Text] [Related]
11. Anti-angiogenic therapy: concept to clinic.
Young RJ; Reed MW
Microcirculation; 2012 Feb; 19(2):115-25. PubMed ID: 22078005
[TBL] [Abstract][Full Text] [Related]
12. The role of antiangiogenesis therapy: bevacizumab and beyond.
Cortés-Funes H
Clin Transl Oncol; 2009 Jun; 11(6):349-55. PubMed ID: 19531449
[TBL] [Abstract][Full Text] [Related]
13. Antiangiogenic therapy for breast cancer.
Nielsen DL; Andersson M; Andersen JL; Kamby C
Breast Cancer Res; 2010; 12(5):209. PubMed ID: 21067536
[TBL] [Abstract][Full Text] [Related]
14. Vascular endothelial growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer: a review of recent clinical trials.
Lee CB; Socinski MA
Rev Recent Clin Trials; 2007 May; 2(2):117-20. PubMed ID: 18473996
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of angiogenesis inhibitors in advanced non-small cell lung cancer: a systematic review and meta-analysis.
Hong S; Tan M; Wang S; Luo S; Chen Y; Zhang L
J Cancer Res Clin Oncol; 2015 May; 141(5):909-21. PubMed ID: 25373315
[TBL] [Abstract][Full Text] [Related]
16. VEGF inhibitors and prostate cancer therapy.
Aragon-Ching JB; Dahut WL
Curr Mol Pharmacol; 2009 Jun; 2(2):161-8. PubMed ID: 19617926
[TBL] [Abstract][Full Text] [Related]
17. [Effect of angiogenesis inhibitors on renal cell carcinoma].
Bodrogi I
Magy Onkol; 2007; 51(2):145-53. PubMed ID: 17660871
[TBL] [Abstract][Full Text] [Related]
18. Playing only one instrument may be not enough: limitations and future of the antiangiogenic treatment of cancer.
Quesada AR; Medina MA; Alba E
Bioessays; 2007 Nov; 29(11):1159-68. PubMed ID: 17935210
[TBL] [Abstract][Full Text] [Related]
19. [Angiogenesis inhibition: review of the activity of sorafenib, sunitinib and bevacizumab].
Barrascout E; Medioni J; Scotte F; Ayllon J; Mejean A; Cuenod CA; Tartour E; Elaidi R; Oudard S
Bull Cancer; 2010; 97():29-43. PubMed ID: 20418202
[TBL] [Abstract][Full Text] [Related]
20. From single- to multi-target drugs in cancer therapy: when aspecificity becomes an advantage.
Petrelli A; Giordano S
Curr Med Chem; 2008; 15(5):422-32. PubMed ID: 18288997
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
